Novo Nordisk A/S ADR buy Morgan Stanley
Start price
23.01.24
/
50%
€95.40
Target price
23.01.25
€110.32
Performance (%)
-18.03%
End price
24.01.25
€78.20
Summary
This prediction ended on 24.01.25 with a price of €78.20. The price of Novo Nordisk A/S ADR has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -18.03%. Morgan_Stanley has a follow-up prediction for Novo Nordisk A/S ADR, but this time predicts that Novo Nordisk A/S ADR is a Sell. A total of €1.08 was paid as dividends for this prediction. Morgan_Stanley has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Novo Nordisk A/S ADR | -0.156% | -0.156% | -43.958% |
| iShares Core DAX® | 2,55 % | 0,56 % | 14,14 % |
| iShares Nasdaq 100 | 2,74 % | -0,60 % | 30,37 % |
| iShares Nikkei 225® | 6,58 % | 4,34 % | 49,37 % |
| iShares S&P 500 | 1,93 % | -0,51 % | 24,26 % |
Comments by Morgan_Stanley for this prediction
In the thread Novo Nordisk A/S ADR diskutieren
Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $120.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
In the thread Trading Novo Nordisk A/S ADR
Die von Morgan_Stanley gewählte maximale Laufzeit wurde überschritten
Current prediction by Morgan_Stanley for Novo Nordisk A/S ADR
Novo Nordisk A/S ADR
Start price
Target price
Perf. (%)
€45.95
29.09.25
29.09.25
€40.10
29.09.26
29.09.26
-29.71%
13.04.26
13.04.26
